VJOncology is committed to improving our service to you

ESMO Breast 2020 | SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC

VJOncology is committed to improving our service to you

Thomas Bachelot

Thomas Bachelot, MD, PhD, of Centre Léon Bérard, Lyon, France, discusses a subgroup analyses of the SAFIR02-IMMUNO study (NCT02299999) which aimed to determine the efficacy of genome analysis as a therapeutic decision tool for patients with metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter